Ozempic vs Mounjaro: What’s the Real Difference?
The real difference between Ozempic and Mounjaro is the active molecule. Ozempic is semaglutide, which acts on one receptor, GLP-1. Mounjaro is tirzepatide, which acts on two, GLP-1 and GIP. They come from different companies, Novo Nordisk and Eli Lilly, and both are approved for type 2 diabetes rather than weight loss. Everything else people argue about, average weight change and cost, flows from that starting point.
What is actually inside each pen?
Semaglutide mimics one gut hormone that signals fullness and slows stomach emptying. Tirzepatide mimics two, adding a GIP effect on top of the GLP-1 action. That second target is the biological reason the tirzepatide studies have tended to report larger average weight reduction. It does not automatically make it the better choice for a given person, because tolerability, other health conditions, and access all weigh in.
Both were first developed for blood sugar control. The FDA labels list type 2 diabetes as the approved use for Ozempic and Mounjaro, and the prescribing information for each spells out the dosing schedule and the warnings, including a boxed warning about thyroid C-cell tumors seen in rodents. The Ozempic label detail is worth reading before assuming the weight loss and diabetes versions behave identically, since dosing and titration differ across brands.
So why do people talk about them for weight loss?
Because the same molecules are approved for weight management under different names. Semaglutide is sold as Wegovy for chronic weight management, and tirzepatide is sold as Zepbound. When someone searches ozempic vs mounjaro with weight loss in mind, they are usually really comparing the two molecules, and the branded weight-loss products are where most of the trial evidence lives. The FDA has published guidance clarifying which semaglutide products are approved and for what, which matters because the market has been crowded with lookalikes.
See also: Optimizing Energy Consumption With Technology
What does the trial evidence show?
The semaglutide program, the STEP trials, tested the molecule for weight in people with overweight or obesity. STEP 3 paired it with intensive behavioral therapy, STEP 8 compared it against daily liraglutide, and STEP 4 looked at what happens when treatment continues versus stops. The consistent finding across these studies was substantial average weight loss while treatment continued.
The tirzepatide program, the SURMOUNT trials, tested the two-receptor molecule. SURMOUNT-CN studied Chinese adults with obesity, and SURMOUNT-4 examined maintenance after an initial treatment period. Across these, average weight reduction ran higher than the semaglutide figures.
Here is the part that gets misreported. STEP and SURMOUNT were separate programs with different populations, doses, and endpoints. They were not a head-to-head contest for weight, so a clean “X percent versus Y percent” ranking overstates what the data can support. The direction of the difference is real. The precision people attach to it is not.
What happens when treatment stops?
This is where both molecules tell the same uncomfortable story. The STEP 1 trial extension tracked people after semaglutide was withdrawn and found that a large share of lost weight returned over the following year. SURMOUNT-4 showed a similar pattern for tirzepatide: continuing treatment held weight off, while stopping it led to regain. Neither is a course you finish. They manage a chronic condition, and the effect largely depends on staying on the drug.
How do the two compare at a glance?
| Feature | Ozempic | Mounjaro |
|---|---|---|
| Active molecule | Semaglutide | Tirzepatide |
| Receptors targeted | GLP-1 | GLP-1 and GIP |
| Maker | Novo Nordisk | Eli Lilly |
| FDA-approved use | Type 2 diabetes | Type 2 diabetes |
| Weight-loss brand of same molecule | Wegovy | Zepbound |
| Administration | Weekly injection | Weekly injection |
What sets the price you pay?
Both list above a thousand dollars a month, and almost nobody pays list. What decides your cost is whether your plan covers the drug for your diagnosis. Coverage for diabetes is more common than coverage for weight management, and many plans exclude anti-obesity medication as an entire category. When that exclusion applies, switching from one brand to the other rarely changes the answer, because the denial is about the category, not the molecule.
If coverage is denied, cash routes become the real comparison. Both manufacturers now run direct self-pay programs, through Lilly’s channels and Novo’s, that sit well below list, though each carries conditions on dose and refill timing. Compounded versions of these molecules are another route people weigh. Supervised telehealth practices, among them Ro, Hims and Hers, Henry Meds, and FormBlends, publish flat monthly pricing, and a practice-focused explainer on the difference between Ozempic and Mounjaro is one place to see how the molecules are framed for cash payers. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products, which is a real distinction rather than a footnote. They may contain the same active molecule, but they have not been through the process that produced the trial evidence above.
Which one is worth it?
An honest answer refuses to crown a universal winner. Tirzepatide has the larger average weight numbers in its trials, and for many people chasing weight reduction that matters. But the higher figure comes with its own cost and access picture, and semaglutide has the longer track record and a wider set of published maintenance data. For someone whose plan covers one and not the other, the debate is already settled by the formulary. Chasing the higher-performing molecule at three times the out-of-pocket cost is not automatically the smart move, and paying for a compounded product without understanding what that trade involves is a decision that belongs with a prescriber.
Key takeaways
- Ozempic is semaglutide and Mounjaro is tirzepatide; they are different molecules, not brand twins.
- Both are approved for type 2 diabetes; the weight-loss versions are Wegovy and Zepbound.
- Tirzepatide trials show larger average weight loss, but STEP and SURMOUNT were not head to head.
- Weight tends to return after either drug is stopped, so both manage a chronic condition.
- Coverage for your diagnosis, not the brand, usually decides what you pay.
Frequently asked questions
Are Ozempic and Mounjaro the same drug?
No. Ozempic is semaglutide, a single GLP-1 receptor agonist. Mounjaro is tirzepatide, which acts on two receptors, GLP-1 and GIP. They are made by different companies and are not interchangeable.
Are either of these approved for weight loss?
Ozempic and Mounjaro are both approved for type 2 diabetes. The same molecules are sold under separate brand names for weight management: semaglutide as Wegovy and tirzepatide as Zepbound.
Does Mounjaro produce more weight loss than Ozempic?
The tirzepatide trials have shown larger average weight reduction than the semaglutide trials, but these were separate studies with different designs. They were not run head to head against each other for weight.
What happens if I stop taking either one?
Trial extensions for both molecules showed that a meaningful share of lost weight returns after the drug is withdrawn. These are treatments for a chronic condition rather than short courses.
Is a compounded version the same thing?
No. Compounded semaglutide or tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It has not been through the approval process behind the branded trial evidence.
